Your browser doesn't support javascript.
loading
Role of Trientine in Hypertrophic Cardiomyopathy: A Review of Mechanistic Aspects.
Ramli, Fitri Fareez; Hashim, Syed Alhafiz Syed; Raman, Betty; Mahmod, Masliza; Kamisah, Yusof.
Afiliação
  • Ramli FF; Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
  • Hashim SAS; Clinical Psychopharmacology Research Unit, Department of Psychiatry Warneford Hospital, University of Oxford, Oxford OX3 7JX, UK.
  • Raman B; Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
  • Mahmod M; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.
  • Kamisah Y; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.
Pharmaceuticals (Basel) ; 15(9)2022 Sep 14.
Article em En | MEDLINE | ID: mdl-36145368
Abnormality in myocardial copper homeostasis is believed to contribute to the development of cardiomyopathy. Trientine, a copper-chelating drug used in the management of patients with Wilson's disease, demonstrates beneficial effects in patients with hypertrophic cardiomyopathy. This review aims to present the updated development of the roles of trientine in hypertrophic cardiomyopathy. The drug has been demonstrated in animal studies to restore myocardial intracellular copper content. However, its mechanisms for improving the medical condition remain unclear. Thus, comprehending its mechanistic aspects in cardiomyopathy is crucial and could help to expedite future research.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article